In Re Loestrin 24 Fe Antitrust Litigation

Settlements have been reached in a class action lawsuit involving the oral contraceptives Loestrin 24 Fe and Minastrin 24 Fe (the “Settlements”) with the Lupin Defendants, including Lupin Ltd. and Lupin Pharmaceuticals, Inc., and the Warner Chilcott Defendants, including: Defendants Warner Chilcott Co., LLC f/k/a Warner Chilcott Co., Inc., Warner Chilcott (US), LLC, Warner Chilcott Sales (US), LLC, and Watson Laboratories, Inc.; related Warner Chilcott and Watson entities Warner Chilcott plc n/k/a Allergan WC Ireland Holdings Ltd., Warner Chilcott Holdings Co. III, Ltd., Warner Chilcott Corp., Warner Chilcott Laboratories Ireland Limited, Warner Chilcott Limited, and Watson Pharmaceuticals, Inc.; and parent entity Allergan plc. The lawsuit claims that Defendants harmed competition and violated state antitrust, consumer protection, and unjust enrichment laws in the United States and its territories by unlawfully delaying the availability of less expensive generic versions of Loestrin 24 Fe and Minastrin 24 Fe. The Defendants deny this. No one is claiming that Loestrin 24 Fe or Minastrin 24 Fe are unsafe or ineffective.
Commenting Policy: This is a page for people who believe they may be class members for the Loestrin 24 FE Litigation Case. By participating on this page, you are agreeing to our commenting policy, outlined below.
We reserve the right to delete posts containing any of the following elements:
- profanity
- misinformation
- spam
- off-topic / irrelevant
- personal attacks
- promoting violence
- promoting illegal or questionable activities

If you repeatedly violate this policy, you will be removed from our page. If you become a bother to other potential Class members, you will be removed. We appreciate your cooperation and support. If you have a question regarding this page or anything on it, please email us at [email protected].

Thank you!